In agreement, GLP1R agonists have been reported to reduce hepatocarcinogenesis in non-obese chemical carcinogen-induced mouse models of HCC, perhaps by limiting liver pro-tumorigenic metabolic factors such as hepatic insulin resistance, steatosis and inflammation90,91. The gene discussed is INS; the disease is hepatocellular carcinoma.